[Explanation] Recently, the news of the death of a well-known Hong Kong actor Wu Mengda due to liver cancer has once again made cancer a topic of public concern.

There is a medical expert Li Bin in Shijiazhuang, Hebei. He has been working hard for twenty years to find new anti-cancer drugs.

On March 2, the reporter met Li Bin who was working in a laboratory in Shijiazhuang High-tech Zone.

Li Bin graduated from the PLA Air Force Military Medical University with a major in clinical medicine, and his research field is tumor immunology.

In the 1990s, cancer treatments were limited. When Li Bin was working in the hospital, he witnessed many cancer patients leaving in pain after receiving treatment.

  [Concurrent] Li Bin, an expert on tumor immunology

  We thought at that time that if we can find more tumor-specific targets and then develop new drugs for multi-target treatment of tumors, the clinical efficacy may be greatly improved. Based on this idea, we began to work on the frontier of tumor multi-target drugs. It is the screening of tumor-specific targets.

  [Explanation] Li Bin is an overseas Chinese and a visiting professor at Stanford University in the United States. According to Li Bin, the research and development of upstream and cutting-edge technologies for multi-target anticancer drugs requires a long cycle, high investment and high risk. When his team was first established There are only three or four people and there is a shortage of funds. In order to maintain the company's operations, they not only do R&D, but also provide outsourcing technical services to universities, colleges, scientific research institutes, and hospitals across the country, and all the proceeds are invested in R&D.

  [Concurrent] Li Bin, an expert on tumor immunology

  (At the time) we firmly believed that this theory was supported, and our Bohai chose the right direction. With the advancement of science and technology and the advancement of society, I think we will be able to break through all kinds of difficulties and achieve our original goals. .

  [Explanation] Li Bin said that a prerequisite for the development of multi-target anti-tumor drugs is to find more specific targets for different tumors. The more targets are found, the conditions for developing multi-target drugs will be more optimized in the future. .

After more than 20 years of unremitting efforts, Li Bin’s team has collected nearly 300,000 clinical specimens, and selected 30,000 tumor tissue specimens that meet the clinical pathological diagnostic criteria, and developed more than 300 targets for 19 common tumors. The MCTL? Multi-target anti-tumor drugs developed by the team have made significant progress.

  [Concurrent] Li Bin, an expert on tumor immunology 

  Up to now, one of our new multi-target lung cancer drugs has entered the clinical (stage) (initiated by the investigator), and there are four to five other varieties (locations) in pre-clinical. We hope that there will be three to five years, and there are several different The new drug can be approved for marketing.

  [Explanation] According to Li Bin, the research results of their team have attracted the attention of many foreign experts.

In April 2017, the first Nobel Prize workstation in Hebei Province was established in Bohai Biotech. The joining of two Nobel Prize winners and six foreign academicians greatly increased the strength of Li Bin's team.

Li Bin said that their ultimate goal of developing new anti-cancer drugs is to enable cancer patients to live with tumors.

  [Concurrent] Li Bin, an expert on tumor immunology 

  My goal is to turn cancer into a chronic disease, make cancer controllable, and make love prolong.

Make cancer patients live with dignity, reduce pain and prolong life.

  Reporter Ai Guangde and Gao Hongchao report from Shijiazhuang.

Editor in charge: [Wang Sishuo]